PLAY PODCASTS
Drug pricing on the agenda for massive infrastructure bill
Episode 18

Drug pricing on the agenda for massive infrastructure bill

Listen to Chris Fleming and Washington University's Rachel Sachs break down H.R. 3, which contains a series of far-reaching drug pricing reforms that could be included as part of a massive infrastructure package proposal.

Health Affairs This Week

April 2, 202110m 7s

Audio is streamed directly from the publisher (media.transistor.fm) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

It's Infrastructure Week and H.R. 3, a far-reaching piece of legislation which contains a series of drug-pricing reforms, is back.

At the end of 2019, the House of Representatives passed H.R. 3 but partisan disagreements prevented the bill from becoming law. Now, elements of H.R. 3 are back on the table as the Biden administration prepares its $2 trillion infrastructure and jobs package.

Washington University's Rachel Sachs joins Health Affairs' Chris Fleming to break down H.R. 3's three main parts and highlight what they mean for the federal budget, pharmaceutical companies, and consumers.

Related Links:

Subscribe: RSS | Apple Podcasts | Spotify | Castro | Stitcher | Deezer | Overcast

Topics

H.R. 3drug pricingdrug pricing reformpharmaceuticalsbiopharmabig pharmaMedicaidrebate rulePBMs